Wilmington Funds Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Wilmington Funds Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	$599K	Buy	61,899 +24,350	+65%	+$217K	0.06%	307
2014 Q1	$312K	Sell	37,549 -8,883	-19%	-$76.1K	0.03%	505
2013 Q4	$392K	Sell	46,432 -674	-1%	-$5.68K	0.04%	473
2013 Q3	$375K	Hold	47,106	–	–	0.04%	476
2013 Q2	$364K	Buy	+47,106	New	+$367K	0.03%	472

Other funds holding PDLI

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wilmington Funds Management's PDLI Position: Q2 2014 in Review

Wilmington Funds Management increased its PDL BioPharma, Inc. (PDLI) stake by 65% in Q2 2014, buying an estimated $217K and bringing the position to 61,899 shares worth $599K. The position accounts for 0.06% of the portfolio, ranked #307.

Wilmington Funds Management first reported a position in PDLI in Q2 2013 and has held it in 5 quarters since. 222 funds tracked by Wall St. Rank hold PDLI as of Q2 2014.

Wilmington Funds Management held 61,899 shares of PDL BioPharma, Inc. worth $599K as of Q2 2014.
Wilmington Funds Management bought 24,350 PDL BioPharma, Inc. shares in Q2 2014, an estimated $217K.
PDL BioPharma, Inc. made up 0.06% of Wilmington Funds Management's portfolio in Q2 2014, its #307 holding.
Wilmington Funds Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and has held it in 5 quarters since.
222 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.